A Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects

Study Identifier
M01-395
CT.gov Identifier
NCT00053378
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Kidneys & Urinary - Other
    • Study Drug
  • paricalcitol injection (Zemplar)
    • Phase
    CSR.ORG
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - ICU patients APACHE III score between 70 - 150 at screening and within 24 hours of enrollment and a whole blood ionized calcium level less than 0.90 mmol/L or corrected whole blood calcium level less than or equal to 7.5 mg/dL.
    Exclusion Criteria:
    - Serum creatinine greater than 2.5 mg/dL

    Protocol Summary

    A study to determine the effect of Zemplar on the regulation of serum calcium levels and the

    need for administration of elemental calcium in hypocalcemic intensive care patients

    Study Locations

    Location
    Status
    Location
    Merced Heart Association
    Merced, California, United States, 95340
    Status
    Not applicable
    Location
    Denver Health Medical Center
    Denver, Colorado, United States, 80204
    Status
    Not applicable
    Location
    Outcomes Research Institute
    Hudson, Florida, United States, 34667
    Status
    Not applicable
    Location
    Florida Hospital
    Orlando, Florida, United States, 32803
    Status
    Not applicable
    Location
    University of Chicago
    Chicago, Illinois, United States, 60637
    Status
    Not applicable
    Location
    Central Baptist Hospital Clinical Research Center
    Lexington, Kentucky, United States, 40503
    Status
    Not applicable
    Showing {first} - {last} of {total} Results